The global "Endoscopic stricture management device market" is estimated to reach at a CAGR of 5.6% during the forecast period (2022-2029).
Strictures can occur anywhere in the GI tract and can be caused by various benign and malignant etiologies. When there is associated clinical impairment or a need to access beyond the stricture for diagnosis or therapy, stricture dilation may be indicated. In the GI lumen and pancreaticobiliary system, a variety of devices are available for use.
Source: DataM Intelligence Analysis (2021)
The factor driving the global endoscopic stricture management device market growth is the technological advancements in endoscopy procedures.
The technological advancements in endoscopy procedures are expected to drive the market growth in the forecast period
The capabilities of interventional gastrointestinal endoscopy have grown significantly over the last few decades. Device and technique advancements have facilitated the translation of novel concepts from bench to bedside. Endoscopists can now safely use submucosal space, also known as third space, thanks to the concept of submucosal endoscopy with a mucosal flap safety valve. In patients with achalasia, the first procedure that used submucosal space was peroral endoscopic myotomy. This technique has since been used successfully to remove subepithelial tumors from the oesophagus and stomach. Endoscopic balloon dilation is a minimally invasive, bowel-length-preserving treatment option for symptomatic CD patients with short fibrotic strictures. EBD has become a well-established treatment modality, frequently delaying or acting as a bridge to surgery.
Benign esophageal strictures (BESs) are noncancerous narrowing of the esophageal lumen. BESs have a wide range of physiopathological mechanisms, including embryonary defects, inflammatory injuries, and iatrogenesis. Furthermore, several etiologic causes may result from the interaction of various mechanisms. Polyvinyl chloride is used to make modern bougies. The dilation procedure consists of passing a guidewire (fluoroscopy-guided or not) through the narrowing of the esophagus, followed by bougination with gradually thicker dilators. When compared to balloon dilation, this procedure generates an axial pressure on the stricture ring and, theoretically, poses a higher risk of esophageal perforation.
Complications associated with stricture dilation is expected to hamper the market growth
Dilation of the esophagus is a procedure used to stretch or dilate abnormal narrowing in the oesophagus. Strictures are narrowing that can occur as a result of a variety of health problems. After esophageal dilation, perforation usually occurs at the site of the stricture. The risk of perforation after balloon dilation is about 3%, but it is higher in patients who have previously received chemotherapy, radiation therapy, or laser therapy. Esophageal balloon dilation should be performed with greater caution in patients who have recently healed perforations or have recently undergone upper gastrointestinal surgery, with continuing esophageal perforation being an absolute contraindication. The risk of perforation, or a hole in the oesophagus, is the most dangerous complication. This can happen in one to four out of every 1,000 dilations. If a perforation occurs, immediate surgery may be required.
COVID-19 Impact Analysis
Although SARS-CoV-2 infection primarily affects the respiratory tract, the disease has several gastrointestinal manifestations. Adequate knowledge on the part of gastroenterologists and endoscopists was critical for their protection as well as the protection of their colleagues in the health care field. Several endoscopy and gastroenterology societies and organizations around the world have outlined protocols and recommendations for practising endoscopists and gastroenterologists. Most of the endoscopy procedures were put on hold. Hence, covid-19 affected the global endoscopic stricture management device market due to low patient intake and procedures.
The stents segment held the largest market share in the global endoscopic stricture management device market
Endoluminal stent placement's clinical applications are expanding. Although most of the literature focuses on treating malignant esophageal stricture, endoluminal stenting has evolved into a versatile and clinically beneficial tool throughout the entire gastrointestinal (GI) tract. Endoscopists with the ability to deploy an increasingly diverse array of stents now can assist a diverse population of patients and fellow physicians with difficult-to-manage disease processes. In general, because of the ease with which they can be removed, covered stents have long been advocated for benign diseases. They are also used in the treatment of cancer because they inhibit tumour growth. They are used to close leaks and fistulae because they prevent extraluminal flow and promote healing.
Covered stents, on the other hand, have a higher rate of migration. Uncovered stents are more commonly used in the gastric outlet, duodenum, and colon. They can also be used for malignant disease when resection with concurrent stent removal is planned. Partially covered stents, theoretically, reduce the risk of stent migration while still allowing for safe endoscopic removal. The most used endoluminal stents are self-expanding metal stents (SEMS) and self-expanding plastic stents (SEPS), which can be placed through the scope (TTS) or over the wire (OTW) with fluoroscopic and endoscopic guidance.
On 04th May 2021, iVascular's BX covered stent iCover received CE mark approval. CoverTech, iVascular's new proprietary technology, is encapsulated in iCover. This technology connects the inner and outer ePTFE layers to ensure total encapsulation.
North America region accounted for the largest market share in the global endoscopic stricture management device market
The rising incidence of gastrointestinal illness and increasing product launches are expected to increase the market growth in this region.
According to Crohn’s & Colitis Foundation of America (CCFA), Inflammatory Bowel Disease (IDB) affects approximately 1.6 million Americans today, a 200,000 increase from the previous year. Every year, up to 70,000 new cases of IBD are diagnosed in the United States. IBD, which includes Crohn's disease and ulcerative colitis, affects up to 1.6 million Americans, most of whom are diagnosed before the age of 35. These chronic, life-long diseases can be managed but not cured. IBD can have a significant impact on a patient's quality of life and a significant financial burden. Endoscopic treatments such as endoscopic balloon dilation (EBD), electroincision, and stent placement have emerged as important options for managing Crohn's disease-related strictures. Bridging the gap between medical and surgical treatment for inflammatory bowel disease.
On December 3rd 2020, Micro-Tech Endoscopy USA launched the GI Dilation product. The new ABC Balloon is available in six diameter sizes, all with a balloon length of 5.5 cm.
Source: DataM Intelligence Analysis (2021)
The global endoscopic stricture management device market is moderately competitive with recent mergers, product launches and partnerships. Some of the major key players in the global endoscopic stricture management device market are Becton, Dickinson and Company, Boston Scientific Corporation, Olympus Corporation, Cook Medical, CONMED Corporation, Merit Medical Systems, Hobbs Medical, Medi-Globe GmbH, Micro-Tech Endoscopy USA and Medorah Meditek Pvt Ltd.
Overview: Olympus has long been recognized as a precision technology pioneer, developing cutting-edge, opto-digital solutions for healthcare, life science, and consumer electronics. Olympus supports the work of medical professionals in the healthcare industry by providing advanced, minimally invasive therapeutic and diagnostic technologies to improve the quality of patient care around the world.
Product Portfolio: Olympus entered the GI Stricture market with its first-generation balloon dilator, EZDilate. Based on physician feedback, EZDilate was created to improve precision during all phases of endoscopic balloon dilation in the oesophagus, pylorus, papilla, and colon.
Key Development: On Oct 28, 2020, Olympus launched HANAROSTENT® Esophagus TTS self-expanding metal stents (SEMS) manufactured by M.I. Tech and distributed exclusively by Olympus in the United States.
The global endoscopic stricture management device market report would provide an access to an approx. 45+market data table, 40+figures and 180 pages.
Get your free sample proposal with a single click!